Cop drives surgeon, donated liver to Thomas Jefferson Hospital after crash
January 16, 2017
Using data science to beat cancer
January 17, 2017
Show all

Early MS Study in Mice Reports New Protein Restores Immune Balance

Animal model research offers a new potential treatment for multiple sclerosis.

Compugen has reported new and promising results from studies on animal models of multiple sclerosis (MS) that support its lead drug candidate, CGEN-15001, as a potential treatment for a variety of autoimmune diseases, including MS.

Specifically, CGEN-15001 was shown to restore immune tolerance and balance in a durable and sustained manner in treated animals, a major unmet research goal for these diseases.

“Autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, type 1 diabetes and psoriasis, are conditions in which the immune system attacks the body’s healthy tissues due to loss of self-tolerance. Restoring this tolerance without impacting the immune system’s ability to fight other diseases is the Holy Grail of immunology,” Anat Cohen-Dayag, CEO and president of Compugen, said in a press release. “Currently, most drugs indicated for autoimmune diseases are general immuno-suppressants, which may lead to serious side effects including infections and an elevated risk of cancer.”

Read full article: Early MS Study in Mice Reports New Protein Restores Immune Balance

Read Full Article: Early MS Study in Mice Reports New Protein Restores Immune Balance

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.